These results implied that treatment of AGNHW could inhibit the expression and activity of MMP-2 and MMP-9, and prevented the degradation of ZO-1 and claudin-5 in the ischemic brains in cerebral ischemia–reperfusion injury. This evidence concerns the gene TJP1 and brain ischemia.